Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals-Reference-Cited by-同舟云学术

Hospitalization Outcomes for Inflammatory Bowel Disease in Teaching vs Nonteaching Hospitals

Published:2019-04-30 Issue:12 Volume:25 Page:1974-1982
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Dalal Rahul S¹,Vajravelu Ravy K²,Lewis James D²,Lichtenstein Gary R²

Affiliation:

1. Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

2. Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Abstract

Teaching hospitals are known for higher inpatient costs compared to community centers. We therefore assessed the impact of hospital teaching status on IBD hospitalization outcomes and found that increased resource utilization is driven by disease complexity, not hospital teaching status.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/25/12/1974/30746005/izz089.pdf

Reference29 articles.

1. Prevalence of inflammatory bowel disease among adults aged ≥18 years - United States, 2015;Dahlhamer;MMWR Morb Mortal Wkly Rep.,2016

2. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004;Nguyen;Inflamm Bowel Dis.,2007

3. Trends in hospitalization rates for inflammatory bowel disease in the United States;Bewtra;Clin Gastroenterol Hepatol.,2007

4. Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis;Longobardi;Am J Gastroenterol.,2007

5. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults;Kappelman;Gastroenterology.,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort;Inflammatory Bowel Diseases;2023-10-16

2. 1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States;Inflammatory Bowel Diseases;2023-08-24

3. Impact of Preoperative Factors in Patients With IBD on Postoperative Length of Stay: A National Surgical Quality Improvement Program–Inflammatory Bowel Disease Collaborative Analysis;Diseases of the Colon & Rectum;2023-07-06

4. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure;Inflammatory Bowel Diseases;2023-05-20

5. Effect of Hospital Teaching Status on Mortality and Procedural Complications of Percutaneous Paracentesis in the United States: A Four-Year Analysis of the National Inpatient Sample;Cureus;2022-06-24